Effect of Short- and Long-Term Treatment With Valproate on Carnitine Homeostasis in Humans

Aims: The aim of this study was to identify the mechanisms of hypocarnitinemia in patients treated with valproate. Methods: Plasma concentrations and urinary excretion of carnitine, acetylcarnitine, propionylcarnitine, valproylcarnitine, and butyrobetaine were determined in a patient starting valproate treatment and in 10 patients on long-term valproate treatment. Transport of carnitine and valproylcarnitine by the proximal tubular carnitine transporter OCTN2 was assessed in vitro. Results: In the patient starting valproate, the plasma carnitine and acetylcarnitine levels dropped for 1–3 weeks and had recovered after 3–5 weeks, whereas the plasma levels of propionyl and valproylcarnitine increased steadily over 5 weeks. The renal excretion and excretion fractions (EFs) of carnitine, acetylcarnitine, propionylcarnitine, and butyrobetaine decreased substantially after starting valproate. Compared with controls, patients on long-term valproate treatment had similar plasma levels of carnitine, acetylcarnitine, and propionylcarnitine, whereas valproylcarnitine was found only in patients. Urinary excretion and renal clearance of carnitine, acetylcarnitine, propionylcarnitine, and butyrobetaine were decreased in valproate-treated compared with that in control patients, reaching statistical significance for carnitine. The EFs of carnitine, acetylcarnitine, and propionylcarnitine were <5% of the filtered load in controls and were lower in valproate-treated patients. In contrast, the EF for valproylcarnitine approached 100%, resulting from a low affinity of valproylcarnitine for the carnitine transporter OCTN2 and competition with concomitantly filtered carnitine. Conclusions: The initial drop in plasma carnitine levels of valproate-treated patients is most likely due to impaired carnitine biosynthesis, whereas the recovery of the plasma carnitine levels is explainable by an increased renal expression of OCTN2. Renally excreted valproylcarnitine does not affect renal handling of carnitine in vivo.

[1]  R. Lam,et al.  Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. , 2010, Journal of affective disorders.

[2]  S. Krähenbühl,et al.  The plasma carnitine concentration regulates renal OCTN2 expression and carnitine transport in rats. , 2010, European journal of pharmacology.

[3]  D. D’Amico.  Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials , 2010, Neurological Sciences.

[4]  R. Herrmann,et al.  Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  S. Hamed,et al.  The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: Relationship to blood carnitine status , 2009, Epilepsy Research.

[6]  S. Krähenbühl,et al.  Interaction between pivaloylcarnitine and L-carnitine transport into L6 cells overexpressing hOCTN2. , 2009, Chemico-biological interactions.

[7]  I. Tamai,et al.  Regulation of Octn2 transporter (SLC22A5) by peroxisome proliferator activated receptor alpha. , 2008, Biological & pharmaceutical bulletin.

[8]  S. Krähenbühl,et al.  Pharmacological manipulation of L-carnitine transport into L6 cells with stable overexpression of human OCTN2 , 2008, Cellular and Molecular Life Sciences.

[9]  J. Bourgeois,et al.  Severe acute hyperammonemia after brief exposure to valproate. , 2008, Psychosomatics.

[10]  H. Hasegawa,et al.  Role of Na+/L-carnitine transporter (OCTN2) in renal handling of pivaloylcarnitine and valproylcarnitine formed during pivalic acid-containing prodrugs and valproic acid treatment. , 2008, Drug metabolism and pharmacokinetics.

[11]  R. Ringseis,et al.  Treatment with pharmacological peroxisome proliferator-activated receptor alpha agonist clofibrate causes upregulation of organic cation transporter 2 in liver and small intestine of rats. , 2007, Pharmacological research.

[12]  Jing Shen,et al.  The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial , 2007, The Lancet.

[13]  G. Coppola,et al.  Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet , 2006, Brain and Development.

[14]  S. Krähenbühl,et al.  Effect of L-carnitine on the kinetics of carnitine, acylcarnitines and butyrobetaine in long-term haemodialysis. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  H. Böhles,et al.  Decreased serum carnitine in valproate induced Reye syndrome , 1982, European Journal of Pediatrics.

[16]  S. Krähenbühl,et al.  Determination of carnitine and acylcarnitines in plasma by high-performance liquid chromatography/electrospray ionization ion trap tandem mass spectrometry. , 2004, Rapid communications in mass spectrometry : RCM.

[17]  S. Krähenbühl,et al.  Determination of carnitine and acylcarnitines in urine by high-performance liquid chromatography-electrospray ionization ion trap tandem mass spectrometry. , 2003, Journal of chromatography. A.

[18]  C. DeVane.  Pharmacokinetics, drug interactions, and tolerability of valproate. , 2003, Psychopharmacology bulletin.

[19]  P. Vreken,et al.  Analysis of carnitine biosynthesis metabolites in urine by HPLC-electrospray tandem mass spectrometry. , 2002, Clinical chemistry.

[20]  I. T. de Almeida,et al.  Characterization of plasma acylcarnitines in patients under valproate monotherapy using ESI-MS/MS. , 2001, Clinical biochemistry.

[21]  C. Hoppel,et al.  Fatty acid import into mitochondria. , 2000, Biochimica et biophysica acta.

[22]  S. Krähenbühl,et al.  Decreased carnitine biosynthesis in rats with secondary biliary cirrhosis , 2000, Hepatology.

[23]  J. Bale,et al.  Effect of long-term valproic acid administration on the efficiency of carnitine reabsorption in humans. , 1999, Metabolism: clinical and experimental.

[24]  G. Tsujimoto,et al.  Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter , 1999, Nature Genetics.

[25]  S. Krähenbühl,et al.  Increased urinary excretion of carnitine in patients treated with cisplatin , 1998, European Journal of Clinical Pharmacology.

[26]  J. Nezu,et al.  Molecular and Functional Identification of Sodium Ion-dependent, High Affinity Human Carnitine Transporter OCTN2* , 1998, The Journal of Biological Chemistry.

[27]  Y. Tomoda,et al.  Valproate therapy does not deplete carnitine levels in otherwise healthy children. , 1998, Pediatrics.

[28]  J. Sackellares,et al.  Safety and Efficacy of Divalproex Sodium Monotherapy in Partial Epilepsy , 1997, Neurology.

[29]  S. Krähenbühl,et al.  Carnitine metabolism in patients with chronic liver disease. , 1997, Hepatology.

[30]  J. Sackellares,et al.  Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Depakote Monotherapy for Partial Seizures Study Group. , 1997, Neurology.

[31]  A. Sandor,et al.  Inhibition of carnitine biosynthesis by valproic acid in rats--the biochemical mechanism of inhibition. , 1996, Biochemical pharmacology.

[32]  H. Muro,et al.  Effect of L‐Carnitine Supplementation on Acute Valproate Intoxication , 1996, Epilepsia.

[33]  S. Krähenbühl,et al.  Characterization of L-carnitine transport by rat kidney brush-border-membrane vesicles. , 1995, The Biochemical journal.

[34]  H. Muro,et al.  Determination of urinary valproylcarnitine by gas chromatography-mass spectrometry with selected-ion monitoring. , 1995, Journal of chromatography. B, Biomedical applications.

[35]  S. Krähenbühl,et al.  Relationship between the coenzyme A and the carnitine pools in human skeletal muscle at rest and after exhaustive exercise under normoxic and acutely hypoxic conditions. , 1994, The Journal of clinical investigation.

[36]  H. Thom,et al.  AMMONIA AND CARNITINE CONCENTRATIONS IN CHILDREN TREATED WITH SODIUM VALPROATE COMPARED WITH OTHER ANTICONVULSANT DRUGS , 1991, Developmental medicine and child neurology.

[37]  A. Olson,et al.  Carnitine status of lactoovovegetarians and strict vegetarian adults and children. , 1989, The American journal of clinical nutrition.

[38]  W. Jones,et al.  The effect of peroxisome proliferators on microsomal, peroxisomal, and mitochondrial enzyme activities in the liver and kidney. , 1987, Drug metabolism reviews.

[39]  C. Rebouche,et al.  Carnitine metabolism and function in humans. , 1986, Annual review of nutrition.

[40]  T. Suga,et al.  Enhancement of peroxisomal beta-oxidation in the liver of rats and mice treated with valproic acid. , 1985, Biochemical pharmacology.

[41]  T. Bohan,et al.  Valproylcarnitine: a novel drug metabolite identified by fast atom bombardment and thermospray liquid chromatography-mass spectrometry. , 1985, Clinica chimica acta; international journal of clinical chemistry.

[42]  J. Bremer.  Carnitine--metabolism and functions. , 1983, Physiological reviews.

[43]  W. Parker,et al.  Carnitine deficiency with valproate therapy. , 1983, The Journal of pediatrics.

[44]  F. Endo,et al.  Carnitine deficiency and hyperammonemia associated with valproic acid therapy. , 1982, The Journal of pediatrics.

[45]  C. Hoppel,et al.  Relationship between acid-soluble carnitine and coenzyme A pools in vivo. , 1980, The Biochemical journal.

[46]  F. Binon,et al.  O-acylation of dl-carnitine chloride. , 1967, The Journal of organic chemistry.

[47]  I. Fritz,et al.  The role of acylcarnitine esters and carnitine palmityltransferase in the transport of fatty acyl groups across mitochondrial membranes. , 1965, Proceedings of the National Academy of Sciences of the United States of America.

[48]  I. Fritz.  The effect of muscle extracts on the oxidation of palmitic acid by liver slices and homogenates. , 1955, Acta physiologica Scandinavica.